Recall events
/
Event 79957
Event summary
Timeline bucket April 24, 2018
Product types Drug
Classifications Class II
Statuses Terminated
Recalling firm wording Mylan Pharmaceuticals Inc.
Dossier provenance
Source snapshots represented here
openFDA Drug Enforcement
Report-date coverage
June 20, 2012–July 08, 2026
Known gap: openFDA describes 2004-present coverage, but the current export has no report-date records in this interval.
Enforcement coverage uses report dates; product initiation dates can precede those bounds. Device-enrichment coverage uses FDA event_date_initiated.
How coverage and grouping work
Device root-cause evidence is not applicable to this event.
No grouped product has the official product type device; this is not an unavailable-enrichment finding.
Complete imported group
Every recalled product in this event
2 official enforcement rows
Product dates, classifications, firms, and source wording remain attached to their individual rows.
Opening this dossier never hides products that did not match a prior timeline filter.
drug · product 1 of 2
Amlodipine and Benazapril HCL Capsules, USP, 5 mg/10 mg, 100 count bottles, Mylan Pharmaceuticals, Inc., Morgantown, WV --- NDC 0378-6896-01
D-0819-2018
Recall number D-0819-2018
Initiated April 24, 2018
Classification Class II
Status Terminated
Quantity 25,488 bottles
App-derived interpretation
Manufacturing or process control
reason.manufacturing_process_control · v1.0.0
cGMP Deviations
These labels are deterministic app interpretations, not FDA categories.
Inspect official wording and provenance
Reason for recall cGMP Deviations; cleaning process for equipment used to manufacture the specified batches was not followed according to procedure
Code information Lot Numbers# 3083005, 3083006, 3086121, and 3086122, exp Jan 2019
Distribution pattern Product was distributed throughout United States
Official fact provenance
Dataset openFDA Drug Enforcement
Snapshot published July 16, 2026 07:03
Snapshot SHA-256 b791303a96cde04f35218bb062dc99bbd2aaedb7873ee857564b5dbe373c2651
Raw source locator 0001-drug-enforcement-0001-of-0001.json.zip#results[1462]
FDA event record
· Exact recall-number query on openFDA
drug · product 2 of 2
Amlodipine and Benazapril HCL Capsules, USP, 5 mg/40 mg, 100 count bottles, Mylan Pharmaceuticals, Inc., Morgantown, WV --- NDC 0378-6899-01
D-0820-2018
Recall number D-0820-2018
Initiated April 24, 2018
Classification Class II
Status Terminated
Quantity 12,924 bottles
App-derived interpretation
Manufacturing or process control
reason.manufacturing_process_control · v1.0.0
cGMP Deviations
These labels are deterministic app interpretations, not FDA categories.
Inspect official wording and provenance
Reason for recall cGMP Deviations; cleaning processes for equipment used to manufacture the specified batches was not followed according to procedure
Code information Lot Numbers# 3083008 and 3086124, exp Jan 2019
Distribution pattern Product was distributed throughout United States
Official fact provenance
Dataset openFDA Drug Enforcement
Snapshot published July 16, 2026 07:03
Snapshot SHA-256 b791303a96cde04f35218bb062dc99bbd2aaedb7873ee857564b5dbe373c2651
Raw source locator 0001-drug-enforcement-0001-of-0001.json.zip#results[2151]
FDA event record
· Exact recall-number query on openFDA